Advances in Blood Biomarkers for Alzheimer’s Disease: Ultra-Sensitive Detection Technologies and Impact on Clinical Diagnosis
Yi Zhang(Tianjin Medical University General Hospital), Wei Wu(National Clinical Research Center for Digestive Diseases), Kefan Bi(Jianghan University), Yan Sun(Qingdao University), Lingtong Huang(First Affiliated Hospital Zhejiang University), Jie Wang(Wuhan Institute of Physics and Mathematics), Guoping Peng(Zhejiang University), Linfu Zhou(Guangzhou Institutes of Biomedicine and Health)
Cited by 22
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k
Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease
|Archives of General Psychiatry|2010|402